Sera Prognostics Inc(SERA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.66 | Insider Own | 26.49% | Shs Outstand | 38.5M | Perf Week | 0.49% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | 18.63% | Insider Trans | -0.79% | Shs Float | 29.0M | Perf Month | - |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.14 | Inst Own | 45.96% | Short Float | 0.77% | Perf Quarter | -2.86% |
| Income | -0.03B | P/S | 1149.73 | EPS this Y | 1.87% | Inst Trans | 7.73% | Short Ratio | 9.68 | Perf Half Y | 6.81% |
| Sales | 0.00B | P/B | 1.35 | EPS next 5Y | 9.06% | ROA | -33.47% | Short Interest | 0.22M | Perf YTD | -30.85% |
| Book/sh | 1.51 | P/C | 1.73 | EPS past 3/5Y | 22.3% -0.71% | ROE | -45.03% | 52W High | -47.01% ($3.85) | Perf Year | -39.1% |
| Cash/sh | 1.18 | P/FCF | - | Sales past 3/5Y | -32.89% 26.51% | ROIC | -53.27% | 52W Low | 30.77% ($1.56) | Perf 3Y | 17.92% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 21.75% | Gross Margin | -1228.57% | Volatility(W/M) | 2.22% 3.1% | Perf 5Y | -80.25% |
| Dividend TTM | - | EV/Sales | 529.01 | Sales Y/Y TTM | -35.19% | Oper. Margin | -53282.86% | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.98 | EPS Q/Q | -10.37% | Profit Margin | -47475.71% | RSI (14) | 49.36 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.98 | Sales Q/Q | 76.47% | SMA20 | -0.07% ($2.04) | Beta | 1.14 | Target Price | $5.5 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/11/4 | SMA50 | -0.68% ($2.05) | Rel Volume | 3.74 | Prev Close | $2.06 |
| Employees | 72 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | -16.73% -57.98% | SMA200 | -4.25% ($2.13) | Avg Volume(3M) | 0.02M | Price | $2.04 |
| IPO | 2021/7/15 | Option/Short | Yes/Yes | Trades | 85 | Volume | 85,988 | Change | -0.97% |
A U.S. healthcare diagnostics company that develops and commercializes blood-based biomarker tests designed to assess the risk of pregnancy complications in advance. Its flagship product, the PreTRM test, is used to predict the risk of spontaneous preterm birth in asymptomatic expectant mothers, with the goal of enabling earlier intervention in obstetric care.
Over the past 1 year, on the lower side
47% below its 1-year high.
Traded more than usual. That is 374% of its average volume.
Next earnings report: November 4
2 days to go.
SERA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +1.9% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $114,973. Peers typically go for $143.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -80.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 46.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #88 of 142 in the industry
Based on market cap of $80M.
LUCD#87 Lucid Diagnostics Inc $82M PER - SERA#88 Sera Prognostics Inc $80M PER - 
HYPR#89 Hyperfine Inc $76M PER - 
OM#90 Outset Medical Inc $76M PER - 
MBOT#91 Microbot Medical Inc $73M PER - 
FAQ
What kind of company is SERA?
SERA belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of SERA?
The market cap of SERA is approximately $80M, ranking 4,584 within its sector.
What is the 52-week high and low for SERA?
SERA has recorded a 52-week high of $3.85 and a low of $1.56.
